ALERT 2: Dr. Costantini office:
Dear all,
I unfortunately have to share some sad news with you all.
As you all know we submitted to the Michael J Fox Foundation a project proposal for a clinical trial involving the High Dose Thiamine treatment. Although the pre-proposal was invited for further development (stage 1) unfortunately the proposal has been rejected by the reviewers at stage 2.
The reviewers expressed various concerns and a general skepticism about the impact that thiamine with the protocol developed by Dr. Costantini can actually have on PD. The three reviewers although contradicting each other on specific sections of the review, generally implied that the research is not groundbreaking and novel enough, not very trustworthy, same goes for our design (based on dose titration aka giving each patient its efficient dosage or else no improvements can be seen whereas they would have preferred a one size fits all type of dosage) and the lack of experience and reputation of us as Investigators. Reviewers also pointed out that our estimates concerning the recruitment of patients were far too optimistic (200 patients from two of the largest hospitals in Italy in 12 months), one highlighted that the budget we estimated for the clinical trial was too low to be true and in general said that our proposal is unrealistic and the expected results would not be very relevant to the PD community.
I am very sorry but this is their verdict and we can only accept it even though I personally feel this is a missed opportunity for many PD patients.
Another sad piece of news is that unfortunately Dr. Costantini was found positive to the COVID-19 and as many of you know he is already in extremely precarious health conditions as a consequence of the stroke that followed his surgery last year. He is in the Hospital in Lecce right now and we all warmly hope he can win even this battle and return home safely.
I am sorry I am bringing sadness in this delicate and complicated moment for us all but I promised I would have kept this community informed and updated about Dr. C and our attempts to obtain funds for a clinical trial on HDT, although news this time is particularly bitter.